web analytics
-0.8 C
Munich
Saturday, November 26, 2022

The Inside Scoop on Premier Biomedical Inc (OTCMKTS:BIEI)

Premier Biomedical Inc (OTCMKTS:BIEI) is making a fast move up the charts in sub penny land after the Company jumped on the covid bandwagon announcing the filing of a provisional patent application called “Method for Treating and Curing Covid-19 Infection” According to BIEI management: “We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as “cytokine storm”, via the removal of certain non-structural proteins which the Covid-19 virus needs for replication.”

Microcapdaily has been reporting on BIEI for many years; in March 2017 we stated on BIEI: “The move on BIEI came late last year after the Company’s insistence they may have a cure for cancer coupled with significant insider buying. According to CEO William A. Hartman ”I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis.”

Premier Biomedical Inc (OTCMKTS:BIEI)  bills itself as a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.

Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.

To Find out the inside Scoop on BIEI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEI

On March 23 BIEI announced the filing of a provisional patent application, Method for Treating and Curing Covid-19 Infection, by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. Through its exclusive global patent license agreement, Premier Biomedical will have exclusive rights to practice the invention. The patent application involves the removal of disease-specific antigens via an extracorporeal process. These antigens are associated with the ability of Covid-19 to replicate. By targeting these disease antigens with a complexing agent and causing them to bind together, the resulting molecular compound can then be removed in a brief clinical process.

William A. Hartman, President & CEO of Premier Biomedical, stated, “We are very excited to be involved in the pursuit of a cure for severely ill patients suffering from the Coronavirus pandemic. We have already received verbal agreement from a major university partner that they would be able to produce the necessary specific antibodies in a relatively short period of time. We believe that these antibodies may also be utilized as an intravenous drug therapy for Covid-19 patients in addition to their use in our extracorporeal treatment process. The core of this technology is the selective removal of blood-borne antigens associated with the ability of Covid-19 to replicate, and is consistent with our patented core technology.”

The Company makes the bold claim “Scientists with whom we have consulted believe that our patented process could lead to a cure for Covid-19 without invoking any undesirable side effects, since nothing would be added to the patient’s blood.” According to management:  “Premier has repeatedly proven in the laboratory that we can remove specific selected blood-borne antigens from a similar mixture using our patented technology. This intellectual property is an expansion of our two U.S. granted patents: Sequential Extracorporeal Treatment of Bodily Fluids, US Patent No. 9,216,386, and Utilization of Stents for the treatment of Blood Borne Carcinomas, U.S. Patent No. 8,758,287. Both patents can be downloaded from the Premier Biomedical, Inc. website.

We have a Monster Pick Coming. Subscribe Right Now!

Currently running after the covid claim BIEI has minimal assets, no revenues to date and fast rising debt that has led to massive dilution in the past and likely will again in the future. BIEI is making a fast move up the charts in sub penny land after the Company jumped on the covid bandwagon announcing the filing of a provisional patent application called “Method for Treating and Curing Covid-19 Infection” According to BIEI management: “We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as “cytokine storm”, via the removal of certain non-structural proteins which the Covid-19 virus needs for replication.”  We will be updating on BIEI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BIEI either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.